AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26423502 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide mixed with 0.2% chlorhexidine digluconate
Number of subjects: 55
Study 26423502 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide mixed with normal saline
Number of subjects: 55
Study 23205717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser
Number of subjects: 24
Study 23205717 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO(2) laser
Number of subjects: 24
Study 21724623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegnivacogin 1 mg/kg
Number of subjects: 800
Study 21724623 — intervention group
Group type: COMPARATOR
Intervention: Control agent (anivamersen)
Number of subjects: 800
Study 19633475 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d alone (arm A)
Number of subjects: 50
Study 19633475 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d in combination with bortezomib 1.6 mg/m2 (arm B)
Number of subjects: 50
Study 19633475 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib +/- bortezomib in patients with epidermal growth factor receptor mutations
Number of subjects: 50
Study 16752169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg or 80 mg daily
Number of subjects: 215
Study 16752169 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 215
Study 15324925 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-irradiated minitablets containing ciprofloxacin
Number of subjects: 7
Study 15324925 — intervention group
Group type: COMPARATOR
Intervention: Dry heat sterilisation minitablets containing ciprofloxacin
Number of subjects: 7
Study 15324925 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-irradiation
Number of subjects: 7
Study 11733128 — intervention group
Group type: COMPARATOR
Intervention: Non-plantar heel pain group
Number of subjects: 166
Study 11733128 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar heel pain group
Number of subjects: 166
Study 11733128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient b1
Number of subjects: 166
Study 11733128 — intervention group
Group type: COMPARATOR
Intervention: Coefficient b0
Number of subjects: 166
Study 9223713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized distilled water
Number of subjects: 40
Study 9223713 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (isotonic saline)
Number of subjects: 40
Study 7963104 — intervention group
Group type: EXPERIMENTAL
Intervention: front‐loaded recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 382
Study 7963104 — intervention group
Group type: COMPARATOR
Intervention: anistreplase (APSAC)
Number of subjects: 382
Study 7963104 — intervention group
Group type: COMPARATOR
Intervention: combination thrombolytic therapy
Number of subjects: 382
Study 3311283 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 69
Study 3311283 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 69
Study 30269747 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position, 60 mg prasugrel
Number of subjects: 20
Study 30269747 — intervention group
Group type: COMPARATOR
Intervention: Supine position, 60 mg prasugrel
Number of subjects: 20
Study 26518241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 28
Study 26518241 — intervention group
Group type: COMPARATOR
Intervention: Educational-control program
Number of subjects: 28
Study 24092406 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB leukocyte filtration
Number of subjects: 20
Study 24092406 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 20
Study 22325134 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction (RR) program
Number of subjects: 1258
Study 22325134 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Avoidance (RA) program
Number of subjects: 1258
Study 22325134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1258
Study 20234133 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adjudication of clinical events
Number of subjects: 0
Study 18608053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal gel (microbicide)
Number of subjects: 0
Study 18608053 — intervention group
Group type: COMPARATOR
Intervention: Perceived male partner acceptance
Number of subjects: 0
Study 18608053 — intervention group
Group type: COMPARATOR
Intervention: Qualitative research findings
Number of subjects: 0
Study 15831192 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11942734 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Orange Complex (ROC) 50 mg/d, orally
Number of subjects: 33
Study 11942734 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 healthy volunteers)
Number of subjects: 33
Study 10512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral parallelometer
Number of subjects: 32
Study 10512958 — intervention group
Group type: COMPARATOR
Intervention: Freehand tooth preparations
Number of subjects: 32
Study 10512958 — intervention group
Group type: COMPARATOR
Intervention: Guiding pin
Number of subjects: 32
Study 10512958 — intervention group
Group type: COMPARATOR
Intervention: Extraoral parallelometer
Number of subjects: 32
Study 7719358 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte hydrochloride (0.5 mg/kg)
Number of subjects: 20
Study 7719358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2332986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorambucil and prednisolone
Number of subjects: 65
Study 2332986 — intervention group
Group type: COMPARATOR
Intervention: Prednimustine
Number of subjects: 65
Study 204058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon tablets
Number of subjects: 0
Study 204058 — intervention group
Group type: COMPARATOR
Intervention: Standard antacid
Number of subjects: 0
Study 30689098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask combined with mandibular advancement device
Number of subjects: 0
Study 30689098 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 0
Study 28587616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirococept 10 mg
Number of subjects: 80
Study 28587616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirococept (5-25 mg, dose allocation based on interim analysis)
Number of subjects: 80
Study 28587616 — intervention group
Group type: COMPARATOR
Intervention: Standard cold perfusion fluid (Soltran®)
Number of subjects: 80
Study 26853341 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance exercise training (EX)
Number of subjects: 103
Study 26853341 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control group
Number of subjects: 103
Study 24088295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma screening intervention
Number of subjects: 0
Study 22652183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone dimaleate (85 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles)
Number of subjects: 140
Study 22652183 — intervention group
Group type: COMPARATOR
Intervention: Comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine at prespecified standard doses and schedules)
Number of subjects: 140
Study 22652183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 140
Study 22652183 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 140
Study 21092261 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 5754
Study 21092261 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 5754
Study 18563435 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (2 g/day) + EPA (3 g/day)
Number of subjects: 12
Study 18563435 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 12
Study 15804658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ototopical treatments for chronic suppurative otitis media; details on dosage and duration not available.
Number of subjects: 0
Study 15804658 — intervention group
Group type: COMPARATOR
Intervention: Community-controlled research model; details on specific interventions not available.
Number of subjects: 0
Study 11872916 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin agents
Number of subjects: 0
Study 11872916 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 11872916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 0
Study 11872916 — intervention group
Group type: COMPARATOR
Intervention: Traditional antithrombotic agents
Number of subjects: 0
Study 10510145 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 15
Study 10510145 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 100 mg
Number of subjects: 15
Study 10510145 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 15
Study 10510145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7501537 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation combined with guided imagery
Number of subjects: 0
Study 1384397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone alone by bolus administration
Number of subjects: 170
Study 1384397 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone with a continuous (basal) infusion
Number of subjects: 170
Study 1384397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone in combination with 0.08% bupivacaine by bolus administration
Number of subjects: 170
Study 1384397 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone and bupivacaine, with a concurrent infusion of both drugs
Number of subjects: 170
Study 1384397 — intervention group
Group type: EXPERIMENTAL
Intervention: All four groups
Number of subjects: 170
Study 3893680 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF (6141 cGy/4.5 weeks/69 fractions at 89 cGy every 3‐4 hours, three times a day)
Number of subjects: 124
Study 3893680 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF + Misonidazole (1.25 g/m2 three times weekly for the first 3 weeks)
Number of subjects: 124
Study 3893680 — intervention group
Group type: COMPARATOR
Intervention: CF (5800 cGy/6 weeks/30 fractions)
Number of subjects: 124
Study 31239331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) for BAO
Number of subjects: 165
Study 30032883 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport in a children's ride-on toy car (Group C)
Number of subjects: 108
Study 30032883 — intervention group
Group type: COMPARATOR
Intervention: Transport on a gurney without premedication (Group G)
Number of subjects: 108
Study 30032883 — intervention group
Group type: COMPARATOR
Intervention: Transport on a gurney with oral midazolam 0.5 mg kg-1 (Group M)
Number of subjects: 108
Study 27130263 — intervention group
Group type: EXPERIMENTAL
Intervention: Valveless Trocar Insufflation System (VI)
Number of subjects: 56
Study 27130263 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insufflation System (CI)
Number of subjects: 56
Study 24655936 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° head-down tilt (HDT) for 10 min
Number of subjects: 11
Study 24655936 — intervention group
Group type: COMPARATOR
Intervention: Horizontal supine position (HS)
Number of subjects: 11
Study 23683446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 23683446 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 60
Study 21399855 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group (SG)
Number of subjects: 17
Study 21399855 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study 19526249 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem tablet
Number of subjects: 20
Study 19526249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17510726 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm stainless steel posts
Number of subjects: 40
Study 17510726 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm quartz‐fiber posts
Number of subjects: 40
Study 17510726 — intervention group
Group type: COMPARATOR
Intervention: 5 mm stainless steel posts
Number of subjects: 40
Study 17510726 — intervention group
Group type: COMPARATOR
Intervention: 5 mm quartz‐fiber posts
Number of subjects: 40
Study 17510726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both post systems
Number of subjects: 40
Study 15451335 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral misoprostol (600 microg)
Number of subjects: 100
Study 15451335 — intervention group
Group type: COMPARATOR
Intervention: Repeated dose of oral misoprostol (1200 microg total, given as 600 microg every 4 hours)
Number of subjects: 100
Study 15451335 — intervention group
Group type: COMPARATOR
Intervention: Repeated dose of oral misoprostol (1200 microg total)
Number of subjects: 100
Study 11352373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 2 hour session
Number of subjects: 56
Study 11352373 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention - 2 hour COPD education
Number of subjects: 56
Study 9671370 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Number of subjects: 24
Study 9671370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Number of subjects: 24
Study 7743685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (bolus-infusion of 0.5 mg/kg over 10 min followed by an infusion of 5 micrograms/kg/min up to 20 micrograms/kg/min)
Number of subjects: 12
Study 7743685 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine/nitroglycerin (infusion of 0.05 and 0.5 micrograms/kg/min, respectively, for 4 hours postoperatively)
Number of subjects: 12
Study 2201732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg at bed time
Number of subjects: 12
Study 2201732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7282598 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma vitamin C levels (16.28 +/- 3.75 mg/l) due to supplementation
Number of subjects: 20
Study 7282598 — intervention group
Group type: COMPARATOR
Intervention: Low plasma vitamin C levels (6.15 +/- 3.88 mg/l)
Number of subjects: 20
Study 31578168 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial lung cryobiopsy (TBLC)
Number of subjects: 65
Study 31578168 — intervention group
Group type: COMPARATOR
Intervention: Surgical lung biopsy (SLB)
Number of subjects: 65
Study 31796486 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment (n=101)
Number of subjects: 203
Study 31796486 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment (n=102)
Number of subjects: 203
Study 28100019 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Number of subjects: 170
Study 26520144 — intervention group
Group type: COMPARATOR
Intervention: AC (adriamycin 60 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by docetaxel 100 mg/m(2) with primary GCSF prophylaxis
Number of subjects: 148
Study 26520144 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (5‐fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) followed by docetaxel 75 mg/m(2)
Number of subjects: 148
Study 23640486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic therapy (fenofibrate, niacin, diet, and exercise)
Number of subjects: 0
Study 23640486 — intervention group
Group type: COMPARATOR
Intervention: HIV/ART HDL
Number of subjects: 0
Study 23640486 — intervention group
Group type: COMPARATOR
Intervention: HIV/ART plasma
Number of subjects: 0
Study 22093195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg)
Number of subjects: 4000
Study 22093195 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of aspirin, ramipril, and simvastatin
Number of subjects: 4000
Study 19236773 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed APL
Number of subjects: 143
Study 19236773 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed APL
Number of subjects: 143
Study 19236773 — intervention group
Group type: COMPARATOR
Intervention: HLA‐DR(‐) AML
Number of subjects: 143
Study 19236773 — intervention group
Group type: COMPARATOR
Intervention: DR(‐) AML
Number of subjects: 143
Study 17710007 — intervention group
Group type: EXPERIMENTAL
Intervention: Khan Kinetic Treatment (KKT)
Number of subjects: 44
Study 17710007 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 44
Study 16163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy
Number of subjects: 0
Study 16163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery
Number of subjects: 0
Study 16163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fluorouracil, cisplatin, and radiation
Number of subjects: 0
Study 16163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the dose of radiotherapy or adding a brachytherapy boost
Number of subjects: 0
Study 16163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer targeted therapies
Number of subjects: 0
Study 11528196 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 21
Study 11528196 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg vardenafil
Number of subjects: 21
Study 11528196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of vardenafil (20 mg and 40 mg)
Number of subjects: 21
Study 11528196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9749589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (selegiline) 10 mg/day
Number of subjects: 0
Study 9749589 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label deprenyl treatment
Number of subjects: 0
Study 9749589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9749589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0
Study 7810015 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgrammes daily via Turbuhaler)
Number of subjects: 37
Study 7810015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7810015 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 37
Study 1903317 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 28
Study 1903317 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rTPA)
Number of subjects: 28
Study 1903317 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release preparations of Metoprolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release preparations of Propranolol
Number of subjects: 0
Study 6102896 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol and Propranolol
Number of subjects: 0
Study 31596983 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air cleaners
Number of subjects: 24
Study 31596983 — intervention group
Group type: COMPARATOR
Intervention: Placebo air cleaners
Number of subjects: 24
Study 30760320 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical therapy with Lishui Xiaogu cataplasm plus red light irradiation along with conventional treatment
Number of subjects: 82
Study 30760320 — intervention group
Group type: COMPARATOR
Intervention: Placebo cataplasm plus red light irradiation along with conventional treatment
Number of subjects: 82
Study 30760320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 28190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming group (EGG) (n = 10)
Number of subjects: 20
Study 28190675 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise group (CG) (n = 10)
Number of subjects: 20
Study 26490012 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth program (Text4Heart) delivered via SMS and website, 24-week duration
Number of subjects: 123
Study 26490012 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth program (Text4Heart)
Number of subjects: 123
Study 26490012 — intervention group
Group type: COMPARATOR
Intervention: usual care (traditional CR)
Number of subjects: 123
Study 23663658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (endothelin receptor antagonist) administered for 14 weeks
Number of subjects: 0
Study 23663658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23663658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 21832027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified milk (mean intake of 3.7 μg/d)
Number of subjects: 181
Study 21832027 — intervention group
Group type: COMPARATOR
Intervention: Red meat (control group)
Number of subjects: 181
Study 19636983 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended information
Number of subjects: 147
Study 19636983 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 147
Study 19636983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 17346425 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin (12 subjects)
Number of subjects: 20